Targeted Therapy of Acute Myeloid Leukemia

  • Michael Andreeff

Part of the Current Cancer Research book series (CUCR)

Table of contents

  1. Front Matter
    Pages i-xix
  2. Alison R. Walker, Guido Marcucci
    Pages 1-25
  3. Apoptosis

    1. Front Matter
      Pages 45-45
    2. Prithviraj Bose, Steven Grant
      Pages 67-94
    3. Bing Z. Carter, Michael Andreeff
      Pages 95-121
    4. Ulrike Bacher, Claudia Haferlach, Vera Grossmann, Susanne Schnittger, Torsten Haferlach
      Pages 123-133
    5. Kojima Kensuke, Lyubomir T. Vassilev
      Pages 135-150
  4. Signaling

    1. Front Matter
      Pages 175-175
    2. Lisa S. Chen, Varsha Gandhi
      Pages 177-199
    3. Gabriela Motyckova, Richard M. Stone
      Pages 201-214
    4. Naval Daver, Farhad Ravandi
      Pages 215-231
    5. Naveen Pemmaraju, Jorge Eduardo Cortes
      Pages 233-249
    6. Ramesh Balusu, Warren Fiskus, Kapil N. Bhalla
      Pages 251-273
    7. James A. McCubrey, Linda S. Steelman, Jörg Bäsecke, Alberto M. Martelli
      Pages 275-305
    8. Chezi Ganzel, Jacob M. Rowe
      Pages 325-333
    9. Brandon Beagle, David A. Fruman
      Pages 335-362

About this book

Introduction

This book provides an unprecedented overview of targeted therapies for acute myeloid leukemias. The volume provides comprehensive coverage of the diverse therapeutic strategies that have been developed during the last decade and are now being evaluated in early clinical trials. Authoritative chapters are written by leading research scientists and clinicians, who explain basic concepts and the clinical translation of topics that include the underlying genetic and proteomic abnormalities of AML. The chapter topics include the development of novel nucleoside analogues, the roles of microRNAs, apoptosis regulators Bcl-2 and p53, and of critical cell signaling proteins such as PIM, FLT3, Raf/MEK, PI3K/AKT/mTOR and aurora kinases. In addition, chapters on epigenetic mechanisms, nuclear receptors, cell surface antigens, the hypoxic leukemia microenvironment, stem cells, and leukemia metabolism, provide insight into leukemia cell vulnerabilities. Cell therapies utilizing T-, NK- and mesenchymal stem cells and progress in hematopoietic transplantation strategies complete the overview of the multi-dimensional therapeutic landscape, where  leukemia specialists develop treatment strategies, which are expected to bring forth critical breakthroughs in the field of leukemia. 

Keywords

AML acute myeloid leukemia apoptosis mutation targeted therapy

Editors and affiliations

  • Michael Andreeff
    • 1
  1. 1.Dept. LeukemiaUniversity of Texas MD Anderson Cancer CenterHoustonUSA

Bibliographic information

  • DOI https://doi.org/10.1007/978-1-4939-1393-0
  • Copyright Information Springer-Verlag New York 2015
  • Publisher Name Springer, New York, NY
  • eBook Packages Medicine
  • Print ISBN 978-1-4939-1392-3
  • Online ISBN 978-1-4939-1393-0
  • About this book